ArticleJournal of paediatrics and child health2025
The KiwiDiab First National Paediatric Diabetes Benchmarking Audit: A Report on Children and Adolescents With Diabetes in Aotearoa New Zealand 2023.
Article in Journal of paediatrics and child health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The KiwiDiab First National Paediatric Diabetes Benchmarking Audit: A Report on Children and Adolescents With Diabetes in Aotearoa New Zealand 2023.Journal of paediatrics and child health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
aimTo compare demographics, therapeutics and outcomes in children and adolescents with diabetes in Aotearoa, New Zealand from the KiwiDiab network.
methodsAll cases of type 1 diabetes (T1D) and type 2 diabetes (T2D) from the 13 regional centres that provide care were collated for the 2023 calendar year.
resultsThere were 1849 children and adolescents with diabetes: 1642 (88.8%) had T1D, mean age at diagnosis 9 years (interquartile range [IQR]: 6-12), mean age in clinic 12 years (IQR: 9-14); 47% were female and 69% identified as NZ European, 16% Māori and 8.3% Pacific. Overall, 23% of children and adolescents with T1D achieved an HbA1c level < 53 mmol/mol (7.0%). The mean (±standard deviation) HbA1c for any insulin pump use was 59 ± 11 mmol/mol (7.5% ± 1.0%) compared to 72 ± 19 (8.7% ± 1.8%) for those on multi-daily injections (MDI) and 96 ± 25 (11.0% ± 2.3%) on twice-daily (BD) insulin (p < 0.001). For the 23% of those using automated insulin delivery, mean HbA1c was similar across ethnic groups. However, HbA1c was higher for those on MDI or BD of Pacific or Māori versus European or Asian ethnicity (p < 0.001). There were 151/1849 (8.2%) children and adolescents with T2D: mean age at diagnosis 13 years (IQR: 12-14), age in clinic 14 years (IQR: 12-15); 61% were female, 38% Māori and 42% Pacific.
conclusionsThis inaugural national benchmarking report demonstrates the differences in diabetes technology usage and HbA1c levels for children and adolescents in Aotearoa, New Zealand. This highlights the need for ongoing benchmarking activities on a regular basis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.